VANIVivani Medical Inc
$1.62
$0.25
(18.52%)
Closed $1.60
$0.02
(1.25%)
After Hours
EarningsAug 13
Mkt Cap$116.42M
Vol2.25M
Vivani Scores Major Validation as Novo Nordisk Evaluates Its Ultra Long-Acting Semaglutide Platform
Vivani Medical (NASDAQ:VANI) has taken another step toward advancing its long-acting obesity treatment platform by entering into an agreement with Novo Nordisk, one of the global leaders in GLP-1 therapies. Under the agreement, Novo Nordisk will conduct a non-exclusive internal evaluation of Vivani's investigational semaglutide implant, NPM-139, highlighting growing industry interest in alternative drug delivery technologies for chronic weight management.
24-7 Market News
ClearOne Announces Entry into Merger Agreement with Cortigent, Inc., a Wholly-Owned Subsidiary of Vivani Medical
ClearOne, Inc. (Nasdaq: CLRO) (ClearOne) announced today that it has entered into a definitive agreement and plan of merger (the Agreement) among its wholly-owned subsidiary (MergerSub), Vivani Medical, Inc. (Nasdaq: VANI; Vivani), and Cortigent, Inc. (Cortigent), a wholly-owned subsidiary of...
Business Wire
Vivani Medical (VANI) to Release Quarterly Earnings on Tuesday
Vivani Medical (NASDAQ:VANI) will be releasing its Q1 2026 earnings before the market opens on Tuesday, May 12. (View Earnings Report at...
MarketBeat
Vivani Medical (NASDAQ:VANI) Director Gregg Williams Purchases 1,587,301 Shares
Vivani Medical, Inc. (NASDAQ:VANI - Get Free Report) Director Gregg Williams purchased 1,587,301 shares of the company's stock in a transaction that occurred on Wednesday, April 15th. The stock was...
MarketBeat
Vivani Medical (NASDAQ:VANI) Director Gregg Williams Acquires 1,587,301 Shares
Vivani Medical, Inc. (NASDAQ:VANI - Get Free Report) Director Gregg Williams purchased 1,587,301 shares of the firm's stock in a transaction on Wednesday, April 15th. The shares were purchased at an...
MarketBeat
Vivani Medical, Inc. (NASDAQ:VANI) Sees Large Increase in Short Interest
Vivani Medical, Inc. (NASDAQ:VANI - Get Free Report) saw a significant growth in short interest in March. As of March 31st, there was short interest totaling 532,131 shares, a growth of 65.0% from the March 15th total of 322,575 shares. Currently, 1.2% of the company's stock are sold short. Based...
MarketBeat
Vivani Medical (VANI) Upgraded to Buy: What Does It Mean for the Stock?
Vivani Medical (VANI) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Zacks
HC Wainwright Lifts Earnings Estimates for Vivani Medical
Vivani Medical, Inc. (NASDAQ:VANI - Free Report) - Stock analysts at HC Wainwright increased their Q1 2026 EPS estimates for Vivani Medical in a research note issued to investors on Tuesday, March 31st. HC Wainwright analyst Y. Chen now forecasts that the company will post earnings of ($0.08) per sh...
MarketBeat
HC Wainwright Cuts Vivani Medical (NASDAQ:VANI) Price Target to $3.50
HC Wainwright reduced their price objective on Vivani Medical from $4.00 to $3.50 and set a "buy" rating for the company in a research report on Tuesday...
MarketBeat
<
1
2
...
>
Advertisement|Remove ads.
Latest VANI News
ViewVivani Scores Major Validation as Novo Nordisk Evaluates Its Ultra Long-Acting Semaglutide Platform
24-7 Market News
Why Did CLRO Stock Surge More Than 170% Today?
Stocktwits
ClearOne Announces Entry into Merger Agreement with Cortigent, Inc., a Wholly-Owned Subsidiary of Vivani Medical
Business Wire
Advertisement|Remove ads.